# Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)

> **NCT07221331** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 200 (estimated)

## Conditions studied

- Neurofibromatosis Type 1

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07221331
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-19
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221331, "Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07221331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*